McKesson (MCK) Q3 2025 Earnings
McKesson reported Q3 2025 revenue of $103.15B (+10.1% YoY), missed analyst consensus of $104.14B by $986.3M. Diluted EPS came in at $9.86 (+39.5% YoY), beat the $9.03 consensus by $0.83. McKesson reports across 4 business segments, led by U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Financial Snapshot
Trailing eight quarters through Q3 2025
Q3 2025 Earnings FAQ
Common questions about McKesson's Q3 2025 earnings report.
McKesson (MCK) reported Q3 2025 earnings on November 5, 2025 after market close.
McKesson reported revenue of $103.15B and diluted EPS of $9.86 for Q3 2025.
Revenue missed the consensus estimate of $104.14B by $986.3M. EPS beat the consensus estimate of $9.03 by $0.83.
Compared to the same quarter a year prior, revenue grew 10.1% from $93.7B a year earlier and diluted EPS grew 39.5% from $7.07.
You can read the 8-K earnings release (0000927653-25-000138) and the 10-Q periodic report (0000927653-25-000140) directly on SEC EDGAR. The filing index links above go to sec.gov.